Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Amit Sanyal, MD: A Clinician’s Perspective

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Jun
08
Today In Oncology
Teclistamab in Previously Treated Multiple Myeloma
Addition of Talazoparib to Enzalutamide in Metastatic Androgen Pathway Modulation–Sensitive Prostate Cancer
Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma
Sunvozertinib in NSCLC With EGFR Exon 20 Insertion Mutations
FDA Approves Durvalumab Plus BCG for High-Risk NMIBC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo